IL312263A - Lurbinectedin and atezolizumab combinations - Google Patents

Lurbinectedin and atezolizumab combinations

Info

Publication number
IL312263A
IL312263A IL312263A IL31226324A IL312263A IL 312263 A IL312263 A IL 312263A IL 312263 A IL312263 A IL 312263A IL 31226324 A IL31226324 A IL 31226324A IL 312263 A IL312263 A IL 312263A
Authority
IL
Israel
Prior art keywords
lorbinactadine
atezolizumab
combinations
atezolizumab combinations
Prior art date
Application number
IL312263A
Other languages
English (en)
Hebrew (he)
Inventor
Mu?Oz Salvador Fudio
Rodriguez Luis Gonzaga Paz-Ares
Aix Santiago Ponce
Original Assignee
Pharma Mar Sa
Mu?Oz Salvador Fudio
Paz Ares Rodriguez Luis Gonzaga
Aix Santiago Ponce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa, Mu?Oz Salvador Fudio, Paz Ares Rodriguez Luis Gonzaga, Aix Santiago Ponce filed Critical Pharma Mar Sa
Publication of IL312263A publication Critical patent/IL312263A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL312263A 2021-11-08 2022-11-08 Lurbinectedin and atezolizumab combinations IL312263A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21383013 2021-11-08
PCT/EP2022/081155 WO2023079177A1 (en) 2021-11-08 2022-11-08 Lurbinectedin and atezolizumab combinations

Publications (1)

Publication Number Publication Date
IL312263A true IL312263A (en) 2024-06-01

Family

ID=78820304

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312263A IL312263A (en) 2021-11-08 2022-11-08 Lurbinectedin and atezolizumab combinations

Country Status (9)

Country Link
US (1) US20240415834A1 (https=)
EP (1) EP4430075A1 (https=)
JP (1) JP2024540417A (https=)
KR (1) KR20240099455A (https=)
AU (1) AU2022381992A1 (https=)
CA (1) CA3237009A1 (https=)
IL (1) IL312263A (https=)
MX (1) MX2024005589A (https=)
WO (1) WO2023079177A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228595A1 (en) * 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
WO2025228594A1 (en) * 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102232L (sv) 2001-06-25 2003-02-06 Anoto Ab Förfarande och anordning i ett digitalt kommunikationssystem
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
JP2023503318A (ja) * 2019-11-21 2023-01-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジン製剤で小細胞肺がんを処置する方法

Also Published As

Publication number Publication date
KR20240099455A (ko) 2024-06-28
AU2022381992A1 (en) 2024-05-16
MX2024005589A (es) 2024-05-23
JP2024540417A (ja) 2024-10-31
WO2023079177A1 (en) 2023-05-11
EP4430075A1 (en) 2024-09-18
CA3237009A1 (en) 2023-05-11
US20240415834A1 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
EP4281085A4 (en) MODIFIED DOUBLE-STRANDED OLIGONUCLEOTIDES
EP4262883C0 (en) PEG LIPIDS AND LIPID NANOPARTICLES
EP4137404A4 (en) Multicopter
EP4107782A4 (en) MICROARRAYS
IL291217A (en) Usp30 inhibitors and uses thereof
DK4034535T3 (da) Aza-quinolinforbindelser og anvendelser deraf
EP3957265A4 (en) MICROSCOPE COVER
IL309079A (en) Methods and compositions
IL310931A (en) 6-aza-quinoline derivatives and related uses
EP4017857A4 (en) METTL 16 INHIBITORS AND THEIR USES
EP4198040C0 (de) Pt-dpephos-iod-komplex und pt-dpephos-brom-komplex
EP4063561C0 (en) REFINER SEGMENT
EP4163277C0 (en) NEW PYRAZOLE DERIVATIVES
IL312263A (en) Lurbinectedin and atezolizumab combinations
EP4504190A4 (en) OXADIAZOLE HDAC6 INHIBITORS AND THEIR USES
PL4198001T3 (pl) Kompleks Pt-bifenyl-jod i kompleks Pt-bifenyl-brom
EP4393838C0 (en) SCREW-ON CAP FOR CONTAINERS AND CONTAINER EQUIPPED WITH SAID CAP
EP4289123C0 (de) Containervermittelte anwendungskonfiguration
EP4197995C0 (de) Pt-xanthen-iod-komplex und pt-xanthen-brom-komplex
EP4154884A4 (en) Anti-sars-cov-2 durg
EP4065112A4 (en) Taspase1 inhibitors and uses thereof
EP3840399C0 (en) SPEAKER AND SOUND BAR
EP4137402A4 (en) MULTICOPTER
EP4444282A4 (en) COMBINATIONS
KR20240099208A9 (ko) EGFRvIII-표적화 화합물 및 그의 용도